Ignite Creation Date:
2024-05-06 @ 6:51 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05807659
Status:
RECRUITING
Last Update Posted:
2023-04-11
First Post:
2023-03-29
Brief Title:
Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies
Sponsor:
Sichuan University
Organization:
Sichuan University
Study Overview
Official Title:
Fractionated Busulfan Combined With ChidamideFludarabineCytarabine ChiFAB With Allogeneic Hematopoietic Stem-Cell Transplantation in Non-remission Myeloid Malignancies a Phase II Study
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this single-arm phase II study is to test in patients with non-remission myeloid malignancies undergoing allogeneic hemopoietic stem-cell transplantation allo-HSCT The main question it aims to answer are
The safety and efficacy of fractionated busulfan Combined With ChidamideFludarabineCytarabineChiFAB conditioning regimen in increasing the overall survival rate in patients with non-remission myeloid malignancies after allo-HSCT
The efficacy of fractionated busulfan conditioning regimen in reducing the recurrence rate in patients with non-remission myeloid malignancies after allo-HSCT
Participants will receive fractionated busulfan-based ChiFAB conditioning regimen busulfan 32mgkg d-13 -12 16mgkg d-6-3 fludarabine 35mgm2 d-6-2 cytarabine 1gm2d-6-2 chidamide 30mg d-13-10-6-3 before allo-HSCT
The safety and efficacy of fractionated busulfan Combined With ChidamideFludarabineCytarabineChiFAB conditioning regimen in increasing the overall survival rate in patients with non-remission myeloid malignancies after allo-HSCT
The efficacy of fractionated busulfan conditioning regimen in reducing the recurrence rate in patients with non-remission myeloid malignancies after allo-HSCT
Participants will receive fractionated busulfan-based ChiFAB conditioning regimen busulfan 32mgkg d-13 -12 16mgkg d-6-3 fludarabine 35mgm2 d-6-2 cytarabine 1gm2d-6-2 chidamide 30mg d-13-10-6-3 before allo-HSCT
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None